Metropolis Healthcare Ltd
Microcap 250
₹576.40
+1.35%
Delayed · cached 15 min
Peer comparison
| Company | Price↕ | Market Cap↕ | P/E↕ | P/B↕ | ROE %↕ | ROCE %↕ | Div yield %↕ | Valuation |
|---|---|---|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd. | ₹ 1,960.40 | ₹ 32,780 Cr | 61.74 | 13.05 | 22.30 | 28.00 | 0.83 | Above FV |
| Vijaya Diagnostic Cen Ltd | ₹ 1,425.00 | ₹ 14,677 Cr | 77.78 | 15.31 | 18.30 | 20.50 | 0.00 | Above FV |
| Metropolis Healthcare Ltd | ₹ 576.40 | ₹ 11,958 Cr | 53.47 | 7.90 | 13.60 | 17.80 | 0.00 | Above FV |
| Thyrocare Tech Ltd | ₹ 488.40 | ₹ 7,774 Cr | 54.45 | 14.61 | 28.40 | 35.40 | 1.45 | Above FV |
| Nephrocare Health Serv L | ₹ 624.20 | ₹ 6,277 Cr | 73.70 | 5.61 | 8.83 | 15.30 | 0.00 | Above FV |
| Suraksha Diagnostic Ltd | ₹ 326.55 | ₹ 1,701 Cr | 47.19 | 6.92 | 14.20 | 17.30 | 0.00 | Above FV |
| Krsnaa Diagnostics Ltd | ₹ 486.05 | ₹ 1,655 Cr | 15.97 | 1.61 | 10.90 | 12.70 | 0.00 | Above FV |
| 3B Blackbio Dx Ltd. | ₹ 1,330.90 | ₹ 1,142 Cr | 20.59 | 3.43 | 19.80 | 25.50 | 0.00 | Above FV |
| Health X Platform Limited | ₹ 274.10 | ₹ 872 Cr | — | 1.36 | 0.44 | 0.03 | 0.00 | Above FV |
| Gaudium Ivf N Women H L | ₹ 107.09 | ₹ 779 Cr | 32.35 | 4.39 | 24.60 | 29.50 | 0.00 | Above FV |
| Chandan Healthcare Ltd | — | ₹ 575 Cr | 21.90 | 3.47 | 19.80 | 23.30 | 0.00 | — |
| Invicta Diagnostic Ltd | — | ₹ 81 Cr | 18.20 | 1.79 | 14.00 | 19.40 | 0.00 | — |
Price, market cap, P/E, P/B and dividend yield reflect the live quote (delayed, cached 15 min); ROE/ROCE from reported financials. The highlighted row is the current company. Click a column header to sort. Educational data only.
How to read the peer comparison
This table places the company beside others in the same industry on a few common measures. Comparison adds context that a single company's numbers cannot give on their own.
- Valuation multiples like P/E and P/B are most meaningful within the same industry, because different industries naturally trade at different levels. Comparing a company only to its peers is more useful than to the whole market.
- Return measures (ROE, ROCE) show how efficiently each company turns capital into profit. A company well ahead of or behind its peers here is worth understanding.
- No single column decides anything. A beginner reads the row across — valuation, returns, and size together — and treats the highlighted current company as one data point among its peers.
- Use the sortable headers to rank peers on any measure, but remember that "cheaper" or "higher" on one metric is a starting question, not an answer.
Educational only — not a recommendation to buy, sell, or hold any security.